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Abstract
Background: Metabolic syndrome (MetS) is defined by an accumulation of risk factors that include cardiovascular
disease, diabetes, chronic high blood pressure, obesity, and hypercholesterolaemia which results in an increased risk
of developing serious chronic diseases. MetS is widespread as it is estimated to affect up to 30% of the global
population. For people with MetS who undergo surgery, an emerging body of literature points to significantly
poorer postoperative outcomes compared with non-affected populations. Surgical patients with MetS are at
significantly higher risk of a range of adverse outcomes including death, morbid cardiovascular events, coma,
stroke, renal failure, myocardial infarction, and surgical site infections. Increased complication rates result in
prolonged hospital stays, a greater need for post-hospitalisation care, and reduced effectiveness of surgical
interventions.
Methods/design: We will search the following electronic bibliographic databases: MEDLINE, EMBASE, ScienceDirect,
and CINAHL, and the reference lists of included articles. We will also search for unpublished literature. Two authors
will screen titles and abstract information independently and select studies according to established inclusion and
exclusion criteria. Data will be extracted by the study investigators using Review Manager 5 and will include
information on demographics, incidence, prevalence, and outcome variables. Subgroup analysis and sensitivity
analysis will be performed to assess the heterogeneity of included studies. Meta-analysis will also be carried out if
appropriate study groups are identified. A descriptive narrative for statistical data will also be provided to highlight
findings of the systematic review and meta-analysis.
Discussion: This study will report and summarise adverse outcomes among adult patients with MetS undergoing
surgery across a range of surgical specialties. Developing insights into outcomes of this population of interest is
necessary to develop guidelines towards better management of surgical patients with metabolic syndrome.
Systematic review registration: PROSPERO CRD42016051071
Keywords: Metabolic syndrome, Surgery, Safety, Risk, Prevalence, Complications, Adverse events
Background
Metabolic syndrome (MetS) is a widespread health con-
cern which leads to the development of cardiovascular
disease, diabetes, chronic high blood pressure, obesity,
and hypercholesterolaemia [1]. Individuals with MetS
typically display symptoms of hypertension, increased
fasting glucose, elevated triglycerides, obesity (either
using BMI or waist circumference), and decreased high-
density lipoprotein concentrations [2]. The presence of
any three out of five of these symptoms or risk factors
constitutes a diagnosis of MetS [3]. There are several
definitions for MetS, and while they share the same
overarching risk factors, diagnostic criteria slightly differ
across each definition. The World Health Organization,
a Joint Interim Statement (JIS) produced by leading
health organisations, and the National Cholesterol Edu-
cation Program Adult Treatment Panel III have pro-
duced the most commonly accepted definitions of MetS
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[1, 3, 4]. Using these definitions, an estimated 35 to 40%
of the population in developed countries have MetS [5].
Having MetS increases the risk of developing type 2 dia-
betes mellitus fivefold and cardiovascular disease three-
fold [6]. It is also associated with the occurrence of a
wide range of cancers including colon, pancreatic, liver,
and breast cancer [2].
Complications can be defined as any deviation from
the normal surgical pathway and can occur intraopera-
tively or postoperatively [7]. Having MetS increases the
number of complications during and after surgery when
compared to unaffected populations. Commonly re-
ported adverse events seem to indicate that patients with
MetS experience higher rates of mortality, increased in-
stances of postoperative morbidity including cardiovas-
cular complications, and slower recovery of function
across both cardiac and non-cardiac surgery [8–11].
Non-routine discharge, protracted length of stay, and in-
creased costs associated with hospitalisation are also de-
tailed in the literature [12–14].
Increased surgical mortality is reported among pa-
tients with MetS. In a study of 310,208 patients with
MetS undergoing non-cardiac surgery, a twofold in-
creased risk of death was observed when comparing with
patients without MetS [8]. Mortality is also reported as a
risk among patients with MetS who undergo renal trans-
plant surgery [15]. In cardiac surgery, having MetS in-
creases the risk of mortality in patients undergoing
coronary artery bypass grafting (CABG), with women
particularly affected [10, 16–19], although one study of
100 patients did not detect an increase in the prevalence
of mortality after CABG surgery [20]. In a study report-
ing on outcomes among 1222 patients undergoing aortic
and mitral valve-replacement surgery, significantly
higher rates of mortality were reported by the authors
[21]. MetS also appears to prognosticate mortality after
gastrectomy for gastric cancer as higher mortality was
detected [12].
In addition to increased risks of mortality, patients
with MetS appear to be at risk of perioperative morbid-
ity with varied complications reported across a range of
surgical procedures. For example, patients undergoing
total joint arthroplasty (TJA) with MetS were reported
to experience higher overall complication rates of 49, 8,
and 8% for uncontrolled MetS, controlled MetS, and no
MetS, respectively [11]. Similar studies reported higher
overall complication rates in comparable patient groups
who underwent TJA surgery [22–26]. In one retrospect-
ive cohort study of 1553 patients over 7 years, MetS was
identified as a significant risk factor for deep vein
thrombosis after total joint arthroplasty [27]. Even in
isolated ankle fracture surgery, an increased risk of com-
plications and slower return to independent functional
mobility were reported among patients with MetS [13].
Several complications were documented in patients who
underwent cardiovascular surgery including poorer pa-
tency of vascular grafts, bleeding, dysrhythmia, atelec-
tasis, deep vein thrombosis, stroke, myocardial
infarction, and infection [10, 14, 20, 26, 28, 29].
Postoperative complications are associated with slower
recovery of function, poorer prognosis, extended length
of stay, and discharge to non-routine environments. For
example, the effectiveness of surgical interventions is re-
duced in the presence of MetS with these patients ex-
periencing far poorer long-term surgical and functional
outcomes after CABG surgery [18]. Patients with MetS
are more likely to experience protracted lengths of stay
in the hospital after CABG surgery [14], acute ortho-
paedic trauma [13], spinal fusion surgery [30], total joint
arthroplasty [11], and gastric bypass surgery [31]. How-
ever, no statistically significant difference in the length
of stay between patients with or without MetS has also
been reported in several studies [20, 22, 23]. Patients
with MetS are also more frequently discharged to non-
routine environments (to an acute or subacute rehabili-
tation centre, skilled nursing facilities, and other institu-
tions) [26]. Patients with MetS also experience higher
readmission rates in the first 12 months following liver
transplantation [32] and CABG surgery [14]. As a result,
costs associated with treating surgical patients with
MetS are significantly higher across a range of surgical
types [12, 30, 33].
Considering the wealth of literature on the topic and
the absence of systematic reviews in the area, this review
is both timely and needed. This situation demands the
undertaking of a systematic review of surgical patients
with MetS to articulate risks as well as the development
of a care pathway to better manage these risks. Further
knowledge about the nature and prevalence of complica-
tions from surgery related to MetS is needed to help for-
mulate targeted interventional research studies aimed at
improving surgical outcomes among patients with the
condition. Collating this data is also vital for observing
and recording trends in MetS and surgical outcomes
and to contribute to the design of further prevalence
studies or interventional research.
Objectives
The objective of this review is as follows:
 To evaluate the effect of metabolic syndrome on the
occurrence of surgical complications in adult
surgical patients (18 years or older).
Methods
Protocol
Recommendations from the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses Protocols
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(PRISMA-P) 2015 statements have been used to develop
the methods for undertaking this systematic review [34].
The systematic review protocol has been registered in
the International Prospective Register of Systematic Re-
views (PROSPERO): 41427. A PRISMA-P file is attached
(see Additional file 1)
Eligibility criteria
Population
Adult surgical patients 18 years of age and older with
metabolic syndrome will be included in the review of
studies.
Outcome
The primary outcome will be the risk of surgical compli-
cations in patients with MetS at various time intervals.
We will report risk as incidence rate, incidence propor-
tion, odds, point prevalence, or period prevalence. Inter-
vals are defined as follows:
 Intraoperative period (during surgery)
 Up to 30 days after surgery as short-term
 >26 weeks as long-term
Surgical complications will be broadly defined as any
deviation from the normal surgical pathway and in-
cluded in a summary presentation of findings. We will
primarily address:
 Mortality during surgery and up to 30 days
postoperatively
 Surgical site infection (SSI)
 Cardiovascular complications (e.g. stroke,
arrhythmia, myocardial infarction)
We will record the occurrence of postoperative SSI as
defined by the CDC criteria [35] or the authors’ defin-
ition of SSI. We will not differentiate the depth of infec-
tion. We will document sepsis or septic shock under this
outcome.
We will also record secondary outcomes as follows:
 Readmission within 30 days
 Mortality within 12 months
 Length of stay
 Cost
 Resource usage (as defined by authors)
Study design
Studies will be restricted on the basis of design. Only
retrospective or prospective observational studies, cross-
sectional studies, cohort studies, case-control studies,
and systematic reviews/meta-analyses will be included.
While the authors are not aware of randomised
controlled trials which test interventions for surgical pa-
tients with MetS, this study type will be excluded on the
basis of methodological inappropriateness for answering
the research question posed by the protocol.
Search strategy
We will search the following databases: MEDLINE,
EMBASE, ScienceDirect, and Cumulative Index to Nurs-
ing and Allied Health Literature (CINAHL), and the ref-
erence lists of included articles. Search terms will reflect
various names for MetS such as “metabolic syndrome”,
“syndrome x”, and the “deadly quartet” while a range of
synonyms for “surgery” will be included. The full search
strategy will include only terms relating to or describing
the phenomena of interest and is described in the Ap-
pendix. The search strategy has been peer reviewed by a
research librarian experienced in systematic review
search strategies. All imported data from the search
strategies will be stored in EndNote (ThomsonReuters)
[36]. Duplicates will be removed from the EndNote li-
brary. Data extraction will be managed within Review
Manager 5 (Cochrane) on institutional licence to the in-
stitution of the lead author.
Searches will be limited to peer-reviewed full-text arti-
cles in the English language, and letters, abstracts, and
editorials are to be excluded. There will be no geograph-
ical limitation on the included studies. No date limita-
tions will be placed on the search strategy. The searches
will be re-run immediately prior to the final analyses
and further studies retrieved for inclusion as appropri-
ate. Where necessary, authors of studies will be con-
tacted for further information. Inclusion and exclusion
criteria will be employed rigorously and are presented in
Table 1.
Selection of studies
Two reviewers (PN and NR) will independently screen
titles and abstracts against inclusion and exclusion cri-
teria to identify potential studies for review. Following
the initial search for studies, we will retrieve full-text
copies of articles which are judged as potentially rele-
vant. Two reviewers (PN and NR) will independently as-
sess full-text articles retrieved for compliance with
inclusion and exclusion criteria. As the criteria for defin-
ing MetS may vary, we will accept definitions of MetS as
used by the study authors. Where required and possible,
we will contact study authors where it is unclear if the
study meets inclusion or exclusion criteria. Any discrep-
ancies in studies selected for inclusion in the review will
be marked within data management software and re-
solved through discussion with a third reviewer (CM).
Studies which appeared to be candidates for inclusion
but excluded at this stage of review will be detailed in a
table entitled “Characteristics of Excluded Studies” where
Norris et al. Systematic Reviews  (2017) 6:115 Page 3 of 7
a justification for exclusion will be listed. The final list of
studies included in the review will be verified by all three
reviewers, and a PRISMA flow chart will be provided detail-
ing the steps taken in the full systematic review.
Data extraction and management
Data will be extracted on the following and entered into
Review Manager 5 to ensure the consistency of informa-
tion retrieved and presented across studies [37]:
1. Study details: title, journal, author, year, city, and
country where research was conducted, type of
publication, and funding source
2. Methods: eligibility of study (as per inclusion
criteria), study aim, data collection method,
recruitment, and sampling methods
3. Participant demographics: number of participants,
population demographics, MetS diagnostic criteria
applied, reported complications
4. Outcome measures: estimates of, and data for, point
and period prevalence, cumulative incidence, and
incidence rate of surgical complications in adult
surgical patients with MetS
5. Limitations: study biases as assessed by the Risk of
Bias in Non-randomised Studies of Interventions
(ROBINS-I) assessment tool used and limitations
identified by study authors
Risk of bias
The risk of bias will be assessed for included studies
using the ROBINS-I tool specifically designed for
appraising the quality of studies including conducting
quality appraisal of non-randomised studies in system-
atic reviews [38]. Two reviewers (PN and NR) will ap-
praise studies using the tool with the third reviewer
(CM) to resolve discrepancies. The instrument can be
employed for different study designs as a mechanism to
appraise studies for internal and external validity rele-
vant to assessing prevalence data. The instrument as-
sesses representativeness, recruitment, sample size,
reporting, data coverage, condition reliability, statistical
analysis, and confounding factors using a simple “yes”,
“no”, “unclear”, or “not/applicable”. Results of the assess-
ment will be presented in table format.
We will also perform symmetry of funnel plots and
Egger’s test to identify publication and selective report-
ing bias [39]. We will consider a p value <0.10 to be a
statistically significant indicator of publication bias.
Data collection and analysis
We will follow meta-analysis of observational studies in
epidemiology (MOOSE) guidelines in the conduct of this
review [40]. Data extracted from selected studies for inclu-
sion will be presented in evidence tables. Descriptive nar-
rative will accompany meta-analysis to summarise the
prevalence of outcomes of interest for adult surgical pa-
tients with MetS according to age, surgical type, and
healthcare setting (e.g. hospital, clinic) and any specific
population demographics at risk of developing complica-
tions (e.g. men >65 years of age). Meta-analysis of out-
come variables will be conducted where appropriate in
reporting outcome estimates. The outcome variables will
be grouped to identify similar patient populations and en-
able meta-analyses where the designs of studies are simi-
lar. Incidence and prevalence data will be presented with
corresponding standard error and 95% confidence inter-
vals using the exact binomial method to model variability
of outcome frequency. The exact binomial method pro-
duces an exact confidence interval that is specifically in-
formed by binomial distribution instead of an
approximation to the binomial distribution. We will also
use Poisson distribution where summary data involves
counts of cases and the person-time of follow-up for each
subgroup of interest.
We will meta-analyse data from comparable studies
(where similar measures of frequency and outcome are re-
ported) if two studies or more are available by outcome of
interest. We anticipate that study and patient characteris-
tics will differ across trials as they will likely use different
measures of outcomes across a range of frequencies. We
will therefore apply a random-effect model to incorporate
anticipated heterogeneity in the analysis of data [21].
We will pool study-specific estimates depending on
whether it is continuous or dichotomous data through a
random-effect meta-analysis model. For continuous data,
Table 1 Example inclusion and exclusion criteria
Example inclusion criteria
□ Observational studies (e.g.
cohort study)
□ Diagnosed with metabolic syndrome
with ≥3 risk factors
□ Adult human patients
(18 years or older)
□ Published peer-reviewed articles
□ Undergoing surgery
Example exclusion criteria
Publication type Study design
□ Narrative reviews □ Interventional studies
□ Editorials Study population
□ Government reports □ Animals
□ Books or book chapters □ Children
□ Conference proceedings □ Pregnant women
□ Commentaries Study procedure
□ Consensus statements □ Minor procedures (e.g. lesion removal,
cystoscopy, endoscopy)
□ Clinical guidelines □ Cardiac catheterisation
□ Lectures and
presentations
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we will use the inverse variance approach with random-
effect models to pool the standardised mean difference if
studies employed different measures to calculate the same
outcome or mean difference if studies used identical mea-
sures. For dichotomous variables, we will combine individ-
ual study data using the Mantel-Haenszel method. We
will pool and report effect sizes as well as their 95% confi-
dence limits. If quantitative data cannot be synthesised,
we will use summary tables to describe the MetS defin-
ition, relevant comparator, and outcome of interest.
Where studies have a minimal or major effect on overall
estimates, we will moderate the variance of study-specific
data using the Freeman-Tukey test. Included studies will
be assessed for heterogeneity related to both methodo-
logical and clinical characteristics using Cochrane’s Q test
[23]. In the presence of heterogeneity, subgroup analyses
(e.g. age, sex, setting, and clinical outcome) will be per-
formed and univariate meta-regression (p value <0.10 will
be considered significant given the low power of these
tests) will be carried out in order to estimate the effect of
study-level covariates on the estimates of incidence and
prevalence according to surgical specialty [25].
Sensitivity analyses will be conducted to identify the
study-level factors that best describe the occurrence of
complication. We will also conduct outlier analyses to de-
termine the effects of certain studies on the pooled esti-
mates of surgically related outcomes among the population
of interest [26]. These analyses will indicate how estimated
parameters of a pooled analysis differ if outlier studies are
disregarded. Excluding such studies from a random-effect
analysis will be performed and reported on.
Discussion
This systematic review and meta-analysis is the first of its
kind in addressing surgical complications likely associated
with MetS. We aim to identify and report the rates of com-
plications among surgical patients with MetS, specifically
related to mortality, morbidity, length of stay, and 30-day
readmission. Population demographics associated with the
manifestation of identified risks will be reported and in-
clude findings which will help increase awareness and guide
decision-making to improve the quality of care among the
population of interest. As no other reviews appear to exist
which specifically address the research question posed for
this review, it is anticipated that comparisons will not be
made with similar publications. Finally, conclusions which
draw on highlighted estimations of prevalence and inci-
dence will be provided in this review. The limitations of this
systematic review will be detailed and discussed. Sugges-
tions for future avenues of research will be provided to en-
courage clinical researchers to give attention to reducing
risks faced by surgical patients with MetS.
The authors are not aware of any guidelines developed
which target adult surgical patients with MetS. The
findings of the review will be used to develop criteria for
the initial round of a Delphi study in which a multi-
disciplinary cross section of experts in MetS and surgery
will be invited to develop clinical guidelines for the man-
agement of surgical patients with MetS. The efficacy of
these guidelines in reducing complications will be tested
as part of a broader study investigating patients with
metabolic syndrome undergoing surgery.
Appendix
Table 2 Example search strategies
Search date MEDLINE search strategy
December 12,
2016
(((metabolic syndrome[Title/Abstract] OR syndrome
x[Title/Abstract]) OR “metsy”[Title/Abstract]) OR “deadly
quartet”[Title/Abstract]) AND (((((((((((surgery[Title/
Abstract] OR “surgeries”[Title/Abstract]) OR
“operation”[Title/Abstract]) OR “operative”[Title/
Abstract]) OR “intervention”[Title/Abstract]) OR
“interventions”[Title/Abstract]) OR “operations”[Title/
Abstract]) OR “perioperative”[Title/Abstract]) OR
“intraoperative”[Title/Abstract]) OR “preoperative”[Title/
Abstract]) OR “postoperative”[Title/Abstract]) OR
“surgical”[Title/Abstract]) AND (“1998/01/01”[PDAT] :
“2017/12/31”[PDAT]) AND (“1998/01/01”[PDAT] : “2017/
12/31”[PDAT])
CINAHL search strategy
December 12,
2016
(((TI metabolic syndrome) OR (AB metabolic syndrome))
OR ((TI syndrome x) OR (AB syndrome x)) OR ((TI Metsy)
OR (AB Metsy)) OR ((TI Metsyn) OR (AB Metsyn)) OR ((TI
Deadly Quartet) OR (AB Deadly Quartet))) AND (((TI
intervention) OR (AB intervention)) OR ((TI
interventions) OR (AB interventions)) OR ((TI operation)
OR (AB operation)) OR ((TI operations) OR (AB
operations)) OR ((TI operative) OR (AB operative)) OR
((TI procedure) OR (AB procedure)) OR ((TI procedures)
OR (AB procedures)) OR ((TI surgery) OR (AB surgery))
OR ((TI surgeries) OR (AB surgeries)) OR ((TI surgical) OR
(AB surgical)) OR ((TI preoperative) OR (AB
preoperative)) OR ((TI intraoperative) OR (AB
intraoperative)) OR ((TI postoperative) OR (AB
postoperative)) OR ((TI perioperative) OR (AB
perioperative))) with limiters of a published date from
1998/01/01
ScienceDirect search strategy
December 14,
2016
title-abs-key(metabolic syndrome) OR title-abs-
key(syndrome x) OR title-abs-key(deadly quartet) OR
title-abs-key(metsy) OR title-abs-key(metsyn) AND title-
abs-key(intervention*) OR title-abs-key(operati*) or title-
abs-key(procedure*) OR title-abs-key(surg*) OR title-abs-
key(preoperative) OR title-abs-key(intraoperative) OR
title-abs-key(postoperative) OR title-abs-
key(perioperative) AND LIMIT-TO (yearnav, “2017, 2016,
2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007,
2006, 2005, 2004, 2003, 2002, 2001, 2000, 1999, 1998”)
AND LIMIT-TO (contenttype, “JL, BS”, “Journal”).
EMBASE search strategy
December 14,
2016
‘metabolic syndrome’:ab,ti OR (syndrome:ab,ti AND
x:ab,ti) OR (deadly:ab,ti AND quartet:ab,ti) AND
surgery:ab,ti AND [1998-2016]/py AND [english]/lim
AND [humans]/lim
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